Download this PDF resource of expert recommendations on the optimal use of immune checkpoint inhibitors in patients with advanced NSCLC, including therapy selection and adverse event management.
In this downloadable slideset, Sandra Cuellar, PharmD, BCOP, reviews pharmacy perspectives in the assessment and management of adverse events associated with immune checkpoint therapy in the care of patients with stage III NSCLC.
In this downloadable slideset, Ali McBride PharmD, MS, BCOP, FAzPA, explores the underlying rationale for immune checkpoint inhibitor therapy in the care of patients with stage III NSCLC.
Expert faculty from the 2017-2018 CCO Local Live meeting series “Expert Strategies to Optimize the Treatment of Patients With Squamous NSCLC” answer frequently asked questions about treating squamous NSCLC, including considerations regarding tumor mutational burden, optimal sequencing of therapy, and future directions.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.